Abstract
An antiandrogenic agent flutamide was used in the treatment of one male and 14 female postmenopausal breast cancer patients. Only a mild and transient response was seen in 2 female patients. Therefore, flutamide cannot be used solely in the treatment of female postmenopausal breast cancer.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow Diseases / chemically induced
-
Breast Neoplasms / drug therapy*
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Drug Evaluation
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Humans
-
Injections, Intravenous
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Nausea / chemically induced
-
Pilot Projects
-
Vomiting / chemically induced
Substances
-
Cyclophosphamide
-
Fluorouracil
-
Methotrexate